Comparative In Vitro Effects of Direct Non-Thermal Plasma and Plasma-Activated Medium on U87-MG Glioblastoma and L-929 Fibroblast Cells
This study demonstrates that while direct non-thermal plasma exposure for 60–90 seconds significantly reduces metabolic activity in both U87-MG glioblastoma and L-929 fibroblast cells, undiluted plasma-activated medium selectively inhibits U87-MG glioblastoma cells without affecting the fibroblast line under the tested conditions.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Glioblastoma is a particularly aggressive form of brain cancer that remains one of the most difficult diseases to treat. Despite advances in surgery, radiation, and chemotherapy, the tumor often returns, and survival rates remain low. This resistance stems from the cancer's ability to adapt, hide, and repair itself, often protected by the body's natural blood-brain barrier which blocks many drugs from reaching the tumor. Because conventional methods struggle, scientists are exploring new ways to attack these cells without causing further harm to the patient. One promising avenue involves non-thermal plasma, a state of matter often described as a "cold" gas that is energized to create a mix of reactive chemicals. These chemicals can damage cancer cells while leaving healthy tissue largely unharmed. Researchers are investigating two ways to deliver this treatment: blasting the cells directly with the plasma jet, or treating a liquid medium with the plasma first and then applying that liquid to the cells.
A team of researchers set out to compare these two approaches using human glioblastoma cells and a type of healthy mouse fibroblast cell. Their goal was to see how each method affected the metabolic activity of the cells, which serves as a general indicator of their health and ability to function. The scientists exposed the cancer cells and the healthy cells to direct plasma for short bursts of thirty, sixty, or ninety seconds. In a separate set of experiments, they created plasma-activated water by treating sterile water with the plasma for five minutes, then mixed this liquid into the cells' food supply at various concentrations. After seventy-two hours, they measured how much energy the cells were producing to determine if they were thriving or struggling.
The results showed that the method of delivery mattered significantly. When the cells were hit directly with the plasma jet, the outcome was straightforward but not selective. Exposure for sixty and ninety seconds reduced the metabolic activity of both the cancer cells and the healthy mouse cells. The thirty-second exposure was too brief to cause a noticeable change in either group. This suggests that while direct plasma can slow down or damage cells, it does so indiscriminately under these conditions, affecting both the tumor and the healthy tissue similarly. The researchers noted that they could not determine exactly how the cells died or stopped functioning, only that their energy production dropped.
The story changed when the researchers used the plasma-treated liquid. In this scenario, the two cell types reacted differently. When the cancer cells were treated with the undiluted plasma-activated liquid, their metabolic activity dropped significantly. However, the healthy mouse cells showed a different reaction; when exposed to the same liquid, even at high concentrations, their metabolic activity was higher compared to the untreated controls. The researchers explicitly noted that this increase in metabolic activity cannot be interpreted as increased proliferation or stimulation without direct cell-counting or specific proliferation assays. This suggests that the liquid might reduce the metabolic activity of the cancer cells while producing a different response in the healthy ones, or at least failing to harm them. The researchers observed that this difference was most pronounced with the strongest concentration of the treated liquid, while weaker mixtures did not produce the same clear effect on the cancer cells.
Despite these interesting differences, the study comes with important caveats. The experiments were conducted in a single run with many repeated measurements, rather than being repeated on different days to confirm the results. Furthermore, the healthy cells used were from a mouse, not a human, and they were not brain cells, so the findings do not prove that this treatment would be safe for a human brain. The study also relied on measuring energy production as a proxy for cell health, rather than directly counting dead cells or observing the specific mechanisms of cell death. The authors emphasize that these findings are preliminary and exploratory. They indicate that plasma-activated liquid might offer a way to target glioblastoma cells differently than direct plasma, but they do not yet prove that this approach is a cure or that it is safe for human use. Future work will need to repeat these experiments, test them on human brain tissue, and understand the exact chemical changes in the liquid to determine if this could eventually become a viable treatment.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.